IL130877A0 - Quinoxalines in a triple combination with protease inhibitors and reverse transcriptase inhibitors as medicaments for the treatment of aids - Google Patents
Quinoxalines in a triple combination with protease inhibitors and reverse transcriptase inhibitors as medicaments for the treatment of aidsInfo
- Publication number
- IL130877A0 IL130877A0 IL13087798A IL13087798A IL130877A0 IL 130877 A0 IL130877 A0 IL 130877A0 IL 13087798 A IL13087798 A IL 13087798A IL 13087798 A IL13087798 A IL 13087798A IL 130877 A0 IL130877 A0 IL 130877A0
- Authority
- IL
- Israel
- Prior art keywords
- quinoxalines
- medicaments
- aids
- inhibitors
- treatment
- Prior art date
Links
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 150000003252 quinoxalines Chemical class 0.000 title 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19703131A DE19703131A1 (de) | 1997-01-29 | 1997-01-29 | Verwendung von Chinoxalin in Dreier-Kombination mit Protease-Inhibitoren und Reverse Transkriptaseinhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen |
| PCT/EP1998/000197 WO1998032442A1 (de) | 1997-01-29 | 1998-01-15 | Chinoxaline in dreier-kombination mit proteaseinhibitoren und reverse transkriptaseinhibitoren als arzneimittel zur behandlung von aids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL130877A0 true IL130877A0 (en) | 2001-01-28 |
Family
ID=7818634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13087798A IL130877A0 (en) | 1997-01-29 | 1998-01-15 | Quinoxalines in a triple combination with protease inhibitors and reverse transcriptase inhibitors as medicaments for the treatment of aids |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0977570A1 (es) |
| JP (1) | JP2001511124A (es) |
| KR (1) | KR20000070543A (es) |
| CN (1) | CN1251525A (es) |
| AR (1) | AR011094A1 (es) |
| AU (1) | AU6094098A (es) |
| BR (1) | BR9807523A (es) |
| CA (1) | CA2278773A1 (es) |
| DE (1) | DE19703131A1 (es) |
| ID (1) | ID22414A (es) |
| IL (1) | IL130877A0 (es) |
| NO (1) | NO993670L (es) |
| PL (1) | PL334770A1 (es) |
| SK (1) | SK99899A3 (es) |
| WO (1) | WO1998032442A1 (es) |
| ZA (1) | ZA98679B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6875773B1 (en) | 1998-05-29 | 2005-04-05 | Ben M. Dunn | Combination therapy for treatment of FIV infection |
| CA2374198A1 (en) * | 1998-05-29 | 1999-12-02 | Maki Arai | Combination therapy for treatment of fiv infection |
| GB9821000D0 (en) * | 1998-09-28 | 1998-11-18 | Glaxo Group Ltd | Antiviral combinations |
| AU6329599A (en) * | 1998-09-28 | 2000-04-17 | Glaxo Group Limited | Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester |
| GB9911887D0 (en) * | 1999-05-21 | 1999-07-21 | Glaxo Group Ltd | Methods and medicaments for post exposure prophylaxis of an hiv infection |
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| CO5300399A1 (es) | 2000-02-25 | 2003-07-31 | Astrazeneca Ab | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen |
| AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| US7005439B2 (en) | 2000-06-20 | 2006-02-28 | Astrazeneca Ab | Compounds |
| GB0104050D0 (en) | 2001-02-19 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| AR035230A1 (es) | 2001-03-19 | 2004-05-05 | Astrazeneca Ab | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos |
| GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
| SE0101038D0 (sv) | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
| SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| SE0301369D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
| US7351709B2 (en) | 2004-06-09 | 2008-04-01 | Wyeth | Estrogen receptor ligands |
| TW200738634A (en) | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
| CA2633400A1 (en) * | 2005-12-15 | 2007-06-21 | Bayer Healthcare Ag | Diaryl urea for treating virus infections |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE205837T1 (de) * | 1991-04-15 | 2001-10-15 | Aventis Pharma Gmbh | Chinoxaline, verfahren zu ihrer herstellung und ihre verwendung |
| DE4342024A1 (de) * | 1993-12-09 | 1995-06-14 | Hoechst Ag | Kombinationspräparate, enthaltend ein Chinoxalin und ein Nukleosid |
| DE19506742A1 (de) * | 1995-02-27 | 1996-08-29 | Bayer Ag | Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen |
-
1997
- 1997-01-29 DE DE19703131A patent/DE19703131A1/de not_active Withdrawn
-
1998
- 1998-01-15 ID IDW990759A patent/ID22414A/id unknown
- 1998-01-15 SK SK998-99A patent/SK99899A3/sk unknown
- 1998-01-15 IL IL13087798A patent/IL130877A0/xx unknown
- 1998-01-15 KR KR1019997006788A patent/KR20000070543A/ko not_active Withdrawn
- 1998-01-15 PL PL98334770A patent/PL334770A1/xx unknown
- 1998-01-15 WO PCT/EP1998/000197 patent/WO1998032442A1/de not_active Ceased
- 1998-01-15 CN CN98803782A patent/CN1251525A/zh active Pending
- 1998-01-15 EP EP98905297A patent/EP0977570A1/de not_active Withdrawn
- 1998-01-15 CA CA002278773A patent/CA2278773A1/en not_active Abandoned
- 1998-01-15 AU AU60940/98A patent/AU6094098A/en not_active Abandoned
- 1998-01-15 JP JP53154098A patent/JP2001511124A/ja active Pending
- 1998-01-15 BR BR9807523A patent/BR9807523A/pt not_active Application Discontinuation
- 1998-01-28 AR ARP980100377A patent/AR011094A1/es unknown
- 1998-01-28 ZA ZA98679A patent/ZA98679B/xx unknown
-
1999
- 1999-07-28 NO NO993670A patent/NO993670L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE19703131A1 (de) | 1998-07-30 |
| ZA98679B (en) | 1998-08-05 |
| CN1251525A (zh) | 2000-04-26 |
| NO993670D0 (no) | 1999-07-28 |
| EP0977570A1 (de) | 2000-02-09 |
| AR011094A1 (es) | 2000-08-02 |
| NO993670L (no) | 1999-09-10 |
| JP2001511124A (ja) | 2001-08-07 |
| AU6094098A (en) | 1998-08-18 |
| CA2278773A1 (en) | 1998-07-30 |
| KR20000070543A (ko) | 2000-11-25 |
| SK99899A3 (en) | 2000-03-13 |
| PL334770A1 (en) | 2000-03-13 |
| WO1998032442A1 (de) | 1998-07-30 |
| ID22414A (id) | 1999-10-14 |
| BR9807523A (pt) | 2000-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL130877A0 (en) | Quinoxalines in a triple combination with protease inhibitors and reverse transcriptase inhibitors as medicaments for the treatment of aids | |
| HUP0203367A3 (en) | Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes | |
| AU2001293553A1 (en) | Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment | |
| AU5127098A (en) | Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis | |
| HUP9904367A3 (en) | Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect | |
| IL138732A0 (en) | The use of polyamines in the treatment of dermatological symptoms | |
| AU4289100A (en) | Dihydropyrimidines and their use in the treatment of hepatitis | |
| IL148974A0 (en) | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders | |
| AU5618501A (en) | Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis | |
| ZA975288B (en) | The use of TCET in the prophylaxis and treatment of allergies. | |
| ZA961516B (en) | Use of quinoxalines in combination with protease inhibitors as medicament for treatis aids and/or hiv infections | |
| AU2418499A (en) | Org-5222 in the treatment of depression | |
| GB2383537B (en) | Use of a compound in providing refreshedness on waking and a method for the treatment of drowsiness therewith | |
| AU7688998A (en) | Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema | |
| AU1430099A (en) | Use of galanthamine and galanthamine derivatives in the case of acute functionalbrain damage | |
| IL141056A0 (en) | Protease inhibitors for use in the treatment of psoriasis | |
| HUP0001976A3 (en) | Antiviral protease inhibitors and pharmaceutical compositions | |
| AU9341398A (en) | Protease precursors that can be autocatalytically activated and their use | |
| AU4923100A (en) | Use of the combination of amino acids having an aliphatic side chain and having a basic side chain in topical hair treatment | |
| AU2001260291A1 (en) | Combination of cerivastatin with ace inhibitors and the use thereof in medicaments | |
| AU2001254825A1 (en) | Butenoic acids derivatives and their use in the treatment of rhinitis | |
| GB9613488D0 (en) | HIV protease inhibitors useful in the treatment of aids | |
| HUP0201800A2 (en) | Novel calpains and their use | |
| IL130103A0 (en) | The use of a diarylalkane derivative in the manufacture of a medicament for treatment or prevention of pancreatitis | |
| SI0929516T1 (en) | Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect |